Results 291 to 300 of about 258,738 (344)

Combined modality therapy of esophageal carcinoma

Cancer, 1981
One hundred ten patients with epidermoid carcinoma of the esophagus were treated at the Memorial Sloan-Kettering Cancer Center (MSKCC) with combined modality techniques involving preoperative irradiation (RT) and surgery, and with preoperative chemotherapy (CT), surgery, and irradiation.
Patricia M. McCormack, Cynthia Kosloff, Manjit S. Bains, Robert B. Golbey, Seymour Hopfan, David P. Kelsen, Nael Martini, Rajender K. Ahuja   +7 more
openaire   +3 more sources

Combination modality cancer therapy

International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1988
Coordination compounds for use in therapy, the compounds having the general empirical formula [Rhm Xx Yy ]a in which m is the oxidation state of Rh, X is at least one anionic ligand, Y is at least one neutral ligand, with the proviso that at least one of X and Y is a nitrogen donor ligand, x is an integer from 1 to 6, y is an integer from 1 to 5 or may
Paul Cedric Hydes, Donald H. Picker
openaire   +2 more sources

Combined modality therapy for esophageal cancer

Current Oncology Reports, 1999
Whereas many patients with esophageal carcinoma present with what appears to be localized disease, cure rates with surgical resection alone remain low. Although surgical resection, where feasible, affords patients the best chance of cure, the primary tumor has often invaded local tissues or structures, and occult micrometastases often exist at the time
Mark J. Krasna, Ziv Gamliel
openaire   +3 more sources

Combined Modality Therapy

2014
Radiation therapy can be modified by increasing the effectiveness of radiation on tumors (radiosensitizers), protecting normal tissues (radioprotectors), increasing oxygen concentration, or by using systemic therapy drugs. Radio-protectors are described by their dose reduction factor (DRF) while radio-sensitizers are described by their enhancement ...
Foster D. Lasley, Joseph R. Dynlacht, Indra J. Das, Marc S. Mendonca, David S. Chang   +4 more
openaire   +2 more sources

Combined modality therapy for intracranial tumors

Cancer, 1975
Three types of tumor (supratentorial astrocytoma, medulloblastoma, and craniopharyngioma), each requiring a fundamentally different therapeutic approach, will be used to illustrate the principles and practice of combined treatment in this field. The role of radiotherapy and ways of enhancing the effect of irradiation will be considered.
H. J. G. Bloom, H. J. G. Bloom
openaire   +3 more sources

Combined modality therapy for gynecologic cancer

Current Opinion in Oncology, 1995
The use of combined modality therapy in the primary management of gynecologic cancer continues to be explored. Although early ovarian cancer is treated with postoperative adjuvant treatment, the data to support its value is lacking. In advanced disease, paclitaxel has emerged as the most optimal treatment after maximal cytoreduction.
Gillian Thomas, Ida Ackerman
openaire   +3 more sources

Taxanes in Combined Modality Therapy

2003
The taxanes are a relatively new group of plant-derived chemotherapeutic agents that have been studied quite extensively in both preclinical studies and in clinical trials. This group of drugs, which includes paclitaxel (Taxol) and docetaxel (Taxotere), act as mitotic spindle inhibitors through their promotion of microtubule assembly and retardation of
Hak Choy, Robert MacRae
openaire   +2 more sources

Combined‐modality therapy for gastric cancer

Seminars in Surgical Oncology, 2003
AbstractGastric cancer has a poor prognosis. It is often diagnosed at an advanced stage, and potentially curative treatments often can not be exercised. Even when a curative surgical resection is possible, only a minority of patients survive beyond 5 years, and locoregional failures are frequent among patients undergoing curative resections.
Barry W. Feig, Paul F. Mansfield, James C. Yao, Nora A. Janjan, Peter W.T. Pisters, Jaffer A. Ajani, Christopher H. Crane   +6 more
openaire   +2 more sources

Combined modality therapy for pancreatic cancer

Seminars in Oncology, 2003
In spite of the high mortality in pancreatic cancer, significant progress is being made. This review discusses multimodality therapy for patients with pancreatic cancer. According to several phase II trials and Gastrointestinal Tumor Study Group results, improvements in locoregional control and survival may be achieved when chemotherapy is added to ...
James Y Tsai, Howard Safran, David A. Iannitti   +2 more
openaire   +3 more sources

Combined Modality Therapy in the Elderly Population

Current Treatment Options in Oncology, 2009
The incidence of cancer among older patients continues to rise. The use of combined modality therapy has improved survival in a variety of malignancies, including rectal, head and neck, and lung cancer; however, the addition of chemotherapy increases substantially the toxicities of treatment.
Lilie L. Lin, Stephen M. Hahn
openaire   +3 more sources